Tactile Systems Technology, Inc. TCMD R2K
Company Overview
Tactile Systems Technology, Inc., a medical technology company, develops and provides medical devices to treat underserved chronic diseases in the United States. It offers Flexitouch Plus system, a pneumatic compression device for the treatment of lymphedema, phlebolymphedema, lipedema, venous insufficiencies, and other types of edema and leg ulcers; Entre Plus System, a pneumatic compression device for the at-home treatment of lymphedema, chronic edema, venous insufficiency, and chronic wounds. The company also provides Nimbl, a pneumatic compression platform for the treatment of upper extremity lymphedema; Kylee, a mobile application to help patients learn about lymphedema, track their symptoms, and treatment, as well as to share their progress with their doctor; and AffloVest, a portable high frequency chest wall oscillation vest to treat patients with retained pulmonary secretions resulting from bronchiectasis, cystic fibrosis, and various neuromuscular disorders. Tactile Systems Technology, Inc. was incorporated in 1995 and is headquartered in Minneapolis, Minnesota.
Why Investors Should Care
Net profit has compounded at 22.4% per year over the last five years.
Revenue has grown at a 19.2% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.07.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $329.52M (+12.5% YoY); net profit $19.09M.
- Trailing 12 Months Year-on-year growth — revenue +22.8%, earnings +12.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 19.2%, profit CAGR 22.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 19.20% |
| 1 Year: | 22.80% |
Compounded Profit Growth
| 5 Years: | 22.38% |
| 1 Year: | 12.54% |
Stock Price Performance
| 1 Year: | +184.86% |
| 6 Months: | -4.25% |
| 3 Months: | +14.13% |
| 1 Month: | +8.70% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)51.27 · Neutral
P/E of 32.87 is above the sector median of 25.88 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 19.2% over 5 years.
- Profit CAGR of 22.4% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | TCMD Tactile Systems Technology, Inc. R2K | 28.60 | 32.87 | $645.11M | 0.00% | 12.57% | 9.59% | 19.20% | 22.38% |
| 2 | LLY Eli Lilly and Company SPX | 1,156.63 | 41.13 | $1.03T | 0.60% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 247.02 | 28.66 | $594.63B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.11 | 119.08 | $431.29B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 418.52 | 31.54 | $380.08B | 2.18% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 123.61 | 34.82 | $305.29B | 2.82% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 168.37 | 26.10 | $261.12B | 1.87% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 535.29 | 29.40 | $198.93B | 0.35% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 358.32 | 24.92 | $193.39B | 2.80% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2015 | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | 19.85M | 26.26M | 28.28M | 34.89M | 26.85M | 34.13M | 36.32M | 46.45M | 37.62M | 45.20M | 49.61M | 57.06M | 43.67M | 35.12M | 49.09M | 59.24M | 42.77M | 51.06M | 52.50M | 47.98M | 59.65M | 65.26M | 58.85M | 68.34M | 69.59M | 61.09M | 73.22M | 73.09M | 61.27M | 78.91M | 85.75M | 75.27M |
| Gross Profit | 7.15M | 10.37M | 12.35M | 16.09M | 9.89M | 14.40M | 16.35M | 20.95M | 14.23M | 19.23M | 20.75M | 26.06M | 19.54M | 24.52M | 26.18M | 32.02M | 26.26M | 31.50M | 35.37M | 41.10M | 31.07M | 24.91M | 34.97M | 41.85M | 30.23M | 36.20M | 36.97M | 33.86M | 43.22M | 46.79M | 41.47M | 48.30M | 49.36M | 43.43M | 54.10M | 54.79M | 45.35M | 58.79M | 65.00M | 57.61M |
| Operating Income | -1.48M | 228.00K | 1.46M | 3.25M | -1.79M | 1.79M | 974.00K | 3.29M | -2.93M | 730.00K | 1.26M | 4.93M | -1.83M | 1.31M | 1.37M | 2.14M | -1.80M | 3.05M | 3.20M | 6.05M | -4.45M | -7.96M | 1.79M | 6.99M | -4.08M | -76.00K | -1.37M | -14.90M | -4.09M | -1.62M | -3.81M | 2.06M | 7.99M | -2.96M | 5.85M | 6.78M | -4.54M | 4.08M | 10.96M | -1.53M |
| Net Income | - | 138.00K | 876.00K | - | -980.00K | 988.00K | 492.00K | - | -1.50M | 3.79M | 1.34M | - | -50.00K | 2.57M | 1.75M | - | 1.47M | 2.79M | 2.43M | - | -1.31M | -13.85M | 2.42M | - | -2.27M | 1.30M | -3.35M | - | -4.64M | -2.28M | -1.89M | -100.00K | 22.30M | -2.21M | 4.30M | 5.16M | -2.97M | 3.22M | 8.21M | -1.76M |
| Diluted EPS | -0.51 | -0.12 | 0.03 | 0.06 | -0.45 | 0.04 | 0.01 | 0.13 | -0.09 | 0.20 | 0.07 | 0.12 | 0.00 | 0.13 | 0.09 | 0.12 | 0.08 | 0.14 | 0.12 | 0.22 | -0.07 | -0.72 | 0.12 | 0.61 | -0.12 | 0.07 | -0.17 | -0.78 | -0.23 | -0.11 | -0.09 | 0.00 | 0.94 | -0.09 | 0.18 | 0.21 | -0.13 | 0.14 | 0.36 | -0.08 |
| R&D Expense | - | 1.01M | 1.09M | - | 980.00K | 1.05M | 1.28M | - | 1.12M | 1.47M | 1.12M | - | 1.44M | 1.29M | 1.22M | - | 1.28M | 1.23M | 1.47M | - | 1.68M | 1.10M | 1.10M | - | 1.27M | 1.21M | 1.41M | 1.52M | 1.85M | 1.58M | 2.23M | 1.83M | 1.96M | 2.14M | 2.23M | 2.42M | 1.74M | 2.02M | 2.19M | 2.78M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 47.74M | 62.87M | 84.54M | 109.28M | 143.75M | 189.49M | 187.13M | 208.06M | 246.78M | 274.42M | 292.98M | 329.52M |
| Gross Profit | 35.02M | 45.96M | 61.60M | 80.27M | 102.26M | 134.24M | 132.81M | 148.21M | 175.98M | 195.13M | 216.69M | 250.15M |
| Operating Income | 3.80M | 3.45M | 4.27M | 3.90M | 2.99M | 10.50M | -3.63M | -1.76M | -12.76M | 18.04M | 22.18M | 29.28M |
| Net Income | 2.07M | 1.39M | 2.88M | 5.86M | 6.62M | 10.97M | -620.00K | -11.81M | -17.87M | 28.52M | 16.96M | 19.09M |
| Diluted EPS | 0.02 | -0.15 | 0.15 | 0.31 | 0.34 | 0.56 | -0.03 | -0.60 | -0.89 | 1.23 | 0.70 | 0.82 |
| R&D Expense | 2.84M | 4.31M | 4.48M | 5.06M | 5.29M | 5.17M | 5.26M | 5.66M | 7.09M | 7.82M | 8.83M | 8.48M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 36.97M | 73.94M | 88.45M | 107.07M | 151.75M | 174.09M | 244.27M | 255.00M | 281.44M | 297.92M | 273.94M |
| Total Equity | -7.11M | -6.43M | -5.65M | 59.64M | 72.79M | 89.27M | 112.59M | 124.75M | 128.23M | 121.40M | 193.64M | 216.60M | 218.90M |
| Cash & Equivalents | 6.54M | 5.42M | 7.06M | 30.70M | 23.97M | 20.10M | 22.77M | 47.85M | 28.23M | 21.93M | 61.03M | 94.37M | 83.45M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - | 16.80M | - | 0 |
| Total Liabilities | - | - | 9.70M | 14.30M | 15.66M | 17.80M | 39.16M | 49.34M | 116.04M | 133.60M | 87.80M | 81.33M | 55.04M |
| Current Liabilities | - | - | 9.50M | 13.79M | 14.52M | 16.08M | 21.43M | 26.71M | 34.46M | 64.33M | 41.06M | 40.70M | 40.96M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | 2.40M | 7.03M | 4.19M | 9.01M | 2.51M | 2.79M | 2.63M | 5.21M | 35.85M | 40.66M | 42.81M |
| Investing Cash Flow | - | -615.00K | -11.84M | -14.02M | -14.73M | -2.33M | 20.18M | -82.18M | -1.91M | -2.48M | -2.50M | -2.54M |
| Financing Cash Flow | - | -140.00K | 28.45M | 3.09M | 1.85M | 2.50M | 2.11M | 59.93M | -9.60M | 5.73M | -4.82M | -51.20M |
| Capital Expenditure | -353.00K | -592.00K | -775.00K | -3.75M | -4.20M | -5.45M | -2.06M | -2.10M | -1.78M | -2.32M | -2.39M | -2.38M |
| Free Cash Flow | - | 1.81M | 6.26M | 446.00K | 4.81M | -2.94M | 735.00K | 528.00K | 3.43M | 33.53M | 38.26M | 40.43M |
| Share Buybacks | - | - | - | 493.00K | - | - | - | - | - | - | 3.51M | 26.56M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 73.4% | 73.1% | 72.9% | 73.4% | 71.1% | 70.8% | 71.0% | 71.2% | 71.3% | 71.1% | 74.0% | 75.9% |
| Operating Margin % | 8.0% | 5.5% | 5.1% | 3.6% | 2.1% | 5.5% | -1.9% | -0.8% | -5.2% | 6.6% | 7.6% | 8.9% |
| Net Margin % | 4.3% | 2.2% | 3.4% | 5.4% | 4.6% | 5.8% | -0.3% | -5.7% | -7.2% | 10.4% | 5.8% | 5.8% |
| ROE % | -32.2% | -24.7% | 4.8% | 8.0% | 7.4% | 9.7% | -0.5% | -9.2% | -14.7% | 14.7% | 7.8% | 8.7% |
| ROCE % | - | 12.6% | 7.1% | 5.3% | 3.3% | 8.1% | -2.5% | -0.8% | -6.7% | 7.5% | 8.6% | 12.6% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 7.89% | 1.78M | $50.86M |
| 2 | Morgan Stanley | 6.13% | 1.38M | $39.52M |
| 3 | Dimensional Fund Advisors LP | 4.79% | 1.08M | $30.86M |
| 4 | Cadian Capital Management, LP | 4.62% | 1.04M | $29.75M |
| 5 | Vanguard Capital Management LLC | 4.19% | 945.10K | $27.01M |
| 6 | Acadian Asset Management. LLC | 4.01% | 905.37K | $25.88M |
| 7 | Driehaus Capital Management, LLC | 3.29% | 741.91K | $21.20M |
| 8 | Vanguard Portfolio Management LLC | 2.96% | 668.33K | $19.10M |
| 9 | Federated Hermes, Inc. | 2.93% | 660.96K | $18.89M |
| 10 | Arrowstreet Capital, Limited Partnership | 2.83% | 638.37K | $18.24M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TCMD
Tactile Systems Technology (TCMD) Moves 8.1% Higher: Will This Strength Last? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxOdE5lRS1MU1VqYl9GUlBCOWVxZWM4UzdmeFJBd3NrYktQbmdrTzJYV3lzYXVZY2M0UERDMm40b3BJcEJPWmZDS3V4UEtoeERFd0FYQkZ0X3hDQWFjVi1hbllQQS1JcUxYYVpra24wd0dMVUJXT1pOUHlpYlBDMUNkMUNNRjlTbXNMZFh3dl…
Wearable calf sleeve with FDA clearance set to reach VA and DoD patients - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxQRVR3WXVGSjUxdlNERm9taUp3a3NPNDNwTTR1Yy1iMzFiZS1vQlhiTnM1dHYwQ0NiT0h2WUdmbkZfLXVtb1VHVTRxS2xfcC1naFpKV2NRUUcyT2ptZDUyN0Z4NktMb0pMZDZLdEotc3lUbW81alBiT2tycmt4NktRaFZnSnFSaGltNWxOOT…
Tactile Systems: Clean Balance Sheet, But A Possible Value Trap - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxPVU1BM3FPaVA5dHBha1M0Njg1cFZ4b203QThjSDhKdU9CbUw5QzVfd1ZsUXhIaGVoa3h4R2FxTGJFVE9XTjAzbE5vNmpUc2dVT2QzQkRVOXBzYjUzR0d1eEhrbTRYdlZPM0RsLTU1eHdtQjZEeDJyNEUzRm9yZDFvMmNYdzB3Qm83aXl2Yl…
Price to book forward of Tactile Systems Technology, Inc. – NASDAQ:TCMD - TradingView
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxQSVRMamhmUzRIMGo5OUZzbWlaeDIzMFZYZ3RwWUI3S28tSmI2UUpDSUFvaURiM3FHak8zUFU5OFZrQUJLTVhVYXhuVUM0Mk4wTEdoWEFQU0VMVm5tS1ZuOWt1NmZHcWdWMUJjYnNtcFQ2OG9XRk9HbnctSDJpYURTUEQ0MXQ5dDRqWHdDWm…
TACTILE SYSTEMS TECHNOLOGY I (TCMD) Stock Chart - ChartMill
<a href="https://news.google.com/rss/articles/CBMiZEFVX3lxTFBvWkwyMjg0WVkyaVIxd2FPbkl1a2lzdFlZRjN1X05WdFJMT2RFSFhvX0dUdUh0UEcwMmJKRWhLRFFEb3ZNZmFseDlpaTFhelZ3Q2RwQ0Z2T1VfOWZiNGw4WmNzLTE?oc=5" target="_blank">TACTILE SYSTEMS TECHNOLOGY I (TC…
Tactile Medical signs exclusive VA distribution deal for MyoSleeve By Investing.com - Investing.com Nigeria
<a href="https://news.google.com/rss/articles/CBMixgFBVV95cUxQYTcxSUNWdlN6cUFNZUxPU3pLOG1BX3I5R3N4c1lGQ2JjX0RTR1R4cmN0eC1jMmN0cG9yNDByaW9sMnRMdThZVHBfOUMycnQyUkctS0J6YjZjMFZlc1ZBMU9TUnE0MmI5YkR2Q2RzeVUtdEswWFFlRHFBUXV6VDdpQlhPa1VVNEdxZmFFel…
TCMD — Frequently Asked Questions
What is the current share price of Tactile Systems Technology, Inc. (TCMD)?
As of 2026-07-15 16:51 PDT, Tactile Systems Technology, Inc. (TCMD) trades at $28.60 on NasdaqGM. Its 52-week range is $9.52 to $33.05.
What is the market capitalisation of TCMD?
Tactile Systems Technology, Inc. (TCMD) has a market capitalisation of $645.11M on NasdaqGM.
What is the P/E ratio of TCMD?
TCMD trades at a trailing price-to-earnings (P/E) ratio of 32.87. The industry average P/E is 25.88. Its price-to-book (P/B) ratio is 2.98.
What is the return on equity (ROE) of TCMD?
TCMD has a return on equity (ROE) of 9.59%. Its return on capital employed (ROCE) is 12.57%.
Is TCMD a good stock to buy?
This page provides a data-driven analysis of Tactile Systems Technology, Inc. (TCMD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.